![Table 2 from Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant Table 2 from Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant](https://d3i71xaburhd42.cloudfront.net/8502ba8141604eccd971b70828b6f88c895aa607/3-Table2-1.png)
Table 2 from Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant
![Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study](https://cancerjournal.net/articles/2015/11/3/images/JCanResTher_2015_11_3_612_146056_t1.jpg)
Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study
![Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419635611-gr1.jpg)
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable
![FEC-D chemotherapy guide for patients with breast cancer • Unity Health Toronto - Patient and Family Education - Online Health Library FEC-D chemotherapy guide for patients with breast cancer • Unity Health Toronto - Patient and Family Education - Online Health Library](https://smh.andornot.com/media/documents/PDFs_Database_Collection/73070_PE_FEC-D_chemotherapy_guide_Feb27_2019_V2.pdf?width=180&404=no-img.jpg)
FEC-D chemotherapy guide for patients with breast cancer • Unity Health Toronto - Patient and Family Education - Online Health Library
Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents | PLOS ONE
![Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/d6941f11-43c3-42dd-bd20-2da1b704c0b6/gr1_lrg.jpg)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet
![Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study](https://cancerjournal.net/articles/2015/11/3/images/JCanResTher_2015_11_3_612_146056_t4.jpg)
Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study
The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer | PLOS ONE
![Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study](https://cancerjournal.net/articles/2015/11/3/images/JCanResTher_2015_11_3_612_146056_t5.jpg)
Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study
![Docetaxel, Doxorubicin and Cyclophosphamide (the TAC regimen): An Effective Adjuvant Treatment for Operable Breast Cancer - Miguel Martin, 2006 Docetaxel, Doxorubicin and Cyclophosphamide (the TAC regimen): An Effective Adjuvant Treatment for Operable Breast Cancer - Miguel Martin, 2006](https://journals.sagepub.com/cms/10.2217/17455057.2.4.527/asset/images/large/10.2217_17455057.2.4.527-table1.jpeg)
Docetaxel, Doxorubicin and Cyclophosphamide (the TAC regimen): An Effective Adjuvant Treatment for Operable Breast Cancer - Miguel Martin, 2006
![Study on the role of primary systemic chemotherapy with anthracycline combination schedule in locally advanced breast cancer: long term follow up data - | Semantic Scholar Study on the role of primary systemic chemotherapy with anthracycline combination schedule in locally advanced breast cancer: long term follow up data - | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7d78229b477d28b17932f5e52ec97dc56a21d886/4-Table3-1.png)